85 related articles for article (PubMed ID: 11021187)
1. [Diabetic nephropathy with nephrotic syndrome--apropos of 2 cases. Advantages of combined conversion enzyme inhibitor and non-dihydropyridine calcium antagonist treatment].
Guelpa G
Praxis (Bern 1994); 2000 Aug; 89(34):1331-8. PubMed ID: 11021187
[TBL] [Abstract][Full Text] [Related]
2. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
Bakris GL; Weir MR; DeQuattro V; McMahon FG
Kidney Int; 1998 Oct; 54(4):1283-9. PubMed ID: 9767545
[TBL] [Abstract][Full Text] [Related]
3. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
Katayama S; Kawamori R; Iwamoto Y; Saito I; Kuramoto K;
Hypertens Res; 2008 Aug; 31(8):1499-508. PubMed ID: 18971523
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of angiotensin converting enzyme inhibitor and calcium channel blocker in the treatment of steroid-resistant idiopathic nephrotic syndrome.
Kumar NS; Singh AK; Mishra RN; Prakash J
J Assoc Physicians India; 2004 Jun; 52():454-8. PubMed ID: 15645954
[TBL] [Abstract][Full Text] [Related]
5. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
Moriyama T; Oka K; Ueda H; Imai E
Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
[TBL] [Abstract][Full Text] [Related]
6. Approach to the treatment of diabetic nephropathy.
Burke JM
Pharm Pract Manag Q; 1997 Jul; 17(2):26-35. PubMed ID: 10168175
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
Ogawa S; Mori T; Nako K; Ito S
Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
[TBL] [Abstract][Full Text] [Related]
8. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial.
Boero R; Rollino C; Massara C; Vagelli G; Gonella M; Berto IM; Bajardi P; Perosa P; Malcangi U; Giorgi MP; Ghezzi PM; Borzumati M; Baroni AM; Cogno C; Triolo G; Angelini D; Antonelli A; Quarello F
J Nephrol; 2001; 14(1):15-8. PubMed ID: 11281338
[TBL] [Abstract][Full Text] [Related]
9. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
Ruggenenti P; Perna A; Ganeva M; Ene-Iordache B; Remuzzi G;
J Am Soc Nephrol; 2006 Dec; 17(12):3472-81. PubMed ID: 17082240
[TBL] [Abstract][Full Text] [Related]
10. Ameliorating effects of conventional therapy on declining renal function in patients with diabetic nephropathy.
Machimura H
Tokai J Exp Clin Med; 1991 Oct; 16(3-4):187-92. PubMed ID: 1811352
[TBL] [Abstract][Full Text] [Related]
11. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
12. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
14. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
[TBL] [Abstract][Full Text] [Related]
15. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
16. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
Remuzzi G; Macia M; Ruggenenti P
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S90-7. PubMed ID: 16565256
[TBL] [Abstract][Full Text] [Related]
17. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
Björck S; Aurell M
J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
20. The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes.
Rubio-Guerra AF; Vargas-Robles H; Vargas-Ayala G; Rodriguez-Lopez L; Escalante-Acosta BA
Clin Exp Hypertens; 2008 Oct; 30(7):682-8. PubMed ID: 18855271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
